|
 |
MesalamineThis page contains recent news articles, when available, and an overview of Mesalamine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.A double blind, double dummy, randomized, controlled, multicenter trial on efficacy and safety of AZA vs mesalamine for prevention of clinical relapses in Hépato-Gastro (Abonnement), Salix Pharmaceuticals to Present at Thomas Weisel Partners Conference - Aug 28, 2008 Vapreotide acetate, metoclopramide-ZYDIS(R), balsalazide tablet, granulated mesalamine and rifaximin for additional indications are under development. MarketWatch Salix Pharmaceuticals Reports 2Q2008 Results - Aug 4, 2008 We continue to believe total Company product revenue for 2008 will be approximately $180 million, assuming the approval and launch of granulated mesalamine FOXBusiness Shire Delivers Strong Quarter: Driven by $243m of New Product ... - Jul 31, 2008 Shire's average quarterly market share of the US oral mesalamine market rose to 27.6% in the three months to June 30, 2008 (2007: 19.9%), driven by the MarketWatch imc2 Unveils IntelliBooth 2.0 - Jul 10, 2008 ...for LIALDA™ (mesalamine) and PENTASA® (mesalamine). "The enhancements imc2 made to IntelliBooth allowed us to leverage the conference to maximum effect. Market Wire (press release) Salix Pharmaceuticals to Present at Two Investment Conferences ... - Jul 30, 2008 Vapreotide acetate, metoclopramide-ZYDIS(R), balsalazide tablet, granulated mesalamine and rifaximin for additional indications are under development. MarketWatch Dynepo dropped as Shire places its faith in Vyvanse for growth - Aug 1, 2008 ...contributed $44.7 million to the coffers, up 40%, while the ulcerative colitis therapy Pentasa (mesalamine) was up 11% to $44.8 million. Pharma Times (subscription), Salix Pharmaceuticals to Present at Two Investment Conferences ... - Jul 30, 2008 Vapreotide acetate, metoclopramide-ZYDIS ® , balsalazide tablet, granulated mesalamine and rifaximin for additional indications are under development. Ad-Hoc-News (Pressemitteilung), ViroPharma Provides Update On Upcoming FDA Advisory Committee ... - Jul 9, 2008 ...least the same level of process and scientific discussion that FDA has previously afforded locally acting GI drugs such as cholestyramine, mesalamine, Medical News Today (press release), Salix Initiates Phase 3 For Rifaximin In Non-Constipation ... - 03 Jul 2008 Vapreotide acetate, metoclopramide-ZYDIS®, balsalazide tablet, granulated mesalamine and rifaximin for additional indications are under development. Medical News Today (press release), Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With ... - Jun 17, 2008 Lialda is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of Lialda. FOXBusiness Mesalamine Improves Moderately Active Ulcerative Colitis - Jun 4, 2008 In the study, the investigational tablet and dose were compared to 400 mg mesalamine tablets dosed at 2.4 g/day. Additionally, patients in the study with a EndoNurse, Single-Dose MMX Mesalazine May Be Effective for Ulcerative Colitis - Jun 19, 2008 Clinical and endoscopic remission of active, mild to moderate UC was induced by MMX mesalamine in doses of 2.4 g once a day, 1.2 g twice daily, Medscape (subscription) /CORRECTION -- Salix Pharmaceuticals/ - Jun 12, 2008 Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN(R) for additional indications are under development. Earthtimes (press release), Alaven Pharmaceutical Introduces Kit for UC Patients - Jun 11, 2008 The kit contains ROWASA® (mesalamine) Rectal Suspension Enema 4g/60mL, a treatment for flare symptoms associated with active mild to moderate left-sided UC, EndoNurse, Crohn's Disease Treatment - What Are the Options? - Jun 10, 2008 So you could be advised to try particular drugs such as sulfasalazine, mesalamine and corticosteroids. These are all anti-inflammatory drugs so many people Best Syndication, Salix teams up with Crohn’s & Colitis Foundation of America for ... - Jun 5, 2008 Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN® for additional indications are under development. dBusinessNews New Orleans (press release), Mesalamine Induces Mucosal Healing in Ulcerative Colitis in ... - May 28, 2008 Inform clinicians of the latest medical information about the effect of MMX mesalamine on inducing mucosal healing in ulcerative colitis, as presented at Medscape (subscription) Safety and Efficacy Results Presented From Largest Prospective ... - May 21, 2008 In the study, the investigational tablet and dose were compared to 400 mg mesalamine tablets dosed at 2.4 g/day. Additionally, patients in the study with a FOXBusiness Mesalamine 1-g Once-Daily Suppository as Effective as 0.5 g Three ... - May 22, 2008 Both the mesalamine 1-g suppository once daily and the mesalamine 0.5-g suppository 3 times daily were very well accepted, "but patients preferred to take DG News Salix Pharmaceuticals Reports 1Q2008 Results - May 6, 2008 We intend to expand our presence in the inflammatory bowel disease market with the addition of balsalazide tablet and granulated mesalamine. Business Wire (press release), Full Text - May 29, 2008 And a sulfide-delivering version of mesalamine, a treatment for inflammatory bowel disease that causes similar GI anguish, could be ready for testing later Science Magazine (subscription) Salix Pharmaceuticals Receives Approvable Letter from FDA for ... - May 16, 2008 Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN® for additional indications are under development. WELT ONLINE, Salix Pharmaceuticals to Present at UBS Conference - May 22, 2008 Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN ® for additional indications are under development. Business Wire (press release), Nationwide Awards Recognize Gastroenterology and Endoscopy Nurses ... - May 19, 2008 SGNA, in partnership with Procter & Gamble (P&G) -- the maker of Asacol(R) (mesalamine) delayed-release tablets -- is proud to present this year's national PR Newswire (press release), Salix Presents New Rifaximin Phase IIb Data Demonstrating ... - May 20, 2008 Balsalazide tablet, encapsulated mesalamine granules, vapreotide acetate, metoclopramide-Zydis ® and (XIFAXAN ® ) rifaximin for additional indications are Business Wire (press release), Salix Pharmaceuticals Receives Approvable Letter From FDA for ... - May 17, 2008 Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN(R) for additional indications are under development. RedOrbit, Recommendations for Primary Care of the Patient With Cancer - May 16, 2008 Proctitis may respond to hydrocortisone cream, glucocorticoid retention enemas, mesalamine suppositories, or sulfasalazine. The clinician must remain Abkhazia, UPDATE: Celebrating UC Success Announces Essay Contest Winners - May 12, 2008 ...including Actonel(R) (risedronate sodium) tablets, Asacol(R) (mesalamine) delayed-release tablets, Dantrium(R) (dantrolene sodium) capsules, Didronel(R) CNNMoney.com (press release) Salix Pharma Slips To Q1 Loss; Guides Q2, FY08 - May 6, 2008 ...due primarily to costs associated with ongoing late-stage studies to expand the rifaximin label, studies of granulated mesalamine and initiatives to RTT News, Market Report -- In Play (PG) - May 20, 2008 Procter & Gamble announces safety and fficacy results, patients with moderately active ulcerative colitis receiving an investigational 800 mg mesalamine MSN Money Salix Pharmaceuticals Ltd. Q1 2008 Earnings Call Transcript - May 6, 2008 We retained to expand our progress in the inflammatory bowel disease market with the ignition of Balsalazide Tablet and Granulated Mesalamine. Seeking Alpha, Health Tip: Controlling Crohn's Disease - Apr 18, 2008 Most people with Crohn's are initially treated with mesalamine, a substance that helps control inflammation of the digestive tract. Washington Post, Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the ... - Mar 26, 2008 Shire's GI team has made Lialda the fastest growing brand of mesalamine and with this collaboration we will bolster the frequency of sales calls to our Trading Markets (press release), Salix Pharmaceuticals Announces 1Q2008 Financial Results ... - Apr 22, 2008 Current development projects include balsalazide tablet, metoclopramide-Zydis ® , encapsulated mesalamine granules, vapreotide acetate, and rifaximin for Business Wire (press release), Shire plc: IFRS Results for the Year Ending December 31, 2007 - Mar 25, 2008 LIALDA/MEZAVANT - Ulcerative colitis Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a MSN Money Shire and TAP to co-promote ulcerative colitis drug Lialda - Mar 27, 2008 The three-year agreement involves the co-promotion of Lialda (mesalamine) in the USA, which the UK-headquartered firm launched in the first quarter of 2007 Pharma Times (subscription), Nationwide Awards Recognize Nurses, Associates and Nursing Teams ... - Mar 26, 2008 One of these brands is Asacol(R) (mesalamine) Delayed-Release Tablets, available by prescription only, which is currently celebrating over 15 years of PR Newswire (press release), 3/26/2008 1:15:41 PM Millrock Resources Inc. (MRO.V) said ... - Mar 26, 2008 L) said that it has entered into a co-promotion agreement with TAP Pharmaceutical Products Inc. for Lialda or mesalamine with MMX technology, indicated for RTT News, Shire hits the road with ulcerative colitis patient awareness program - 11 Mar 2008 Shire currently markets UC treatments Lialda (mesalamine) and Pentasa (mesalamine). In addition to this spring's live event tour, Shire has also launched Medical Marketing and Media, Shire Launches Patient Education Forums on Better Managing the ... - Mar 10, 2008 Shire Pharmaceuticals is a specialty biopharmaceutical company that markets once-daily LIALDA(TM) (mesalamine) for the induction of remission in patients PharmaLive.com (press release), Salix Pharmaceuticals Reports 4Q2007 and FY2007 Results - Mar 3, 2008 ...“Highlights for 2007 were the submission of New Drug Applications for balsalazide tablet and granulated mesalamine, the successful completion and outcome of Business Wire (press release), Salix Pharmaceuticals "neutral," target price reduced - Mar 6, 2008 Eisai co-promotion and the launch of the 1100mg Colazal in 2H08 and of Granulated Mesalamine and Metoclopramide-Zydis in early-2009, the analysts add. newratings.com, Salix Pharmaceuticals Brings Colorectal Screening Outreach to ... - Mar 4, 2008 ...include balsalazide tablet, metoclopramide–Zydis®, encapsulated mesalamine granules, vapreotide acetate, and rifaximin for additional indications. WELT ONLINE, Shire plc: Excellent Performance Across All Areas of the Business ... - Feb 21, 2008 LIALDA, the only once-daily oral formulation of mesalamine was approved by the FDA in January 2007 and launched in the US in March 2007, acquiring 8.0% PR Newswire (press release), Salix Pharmaceuticals to Present at Two Investment Conferences ... - Feb 27, 2008 Current development projects include balsalazide tablet, metoclopramide-Zydis®, encapsulated mesalamine granules, vapreotide acetate, and rifaximin for WELT ONLINE, Vyvanse confounds analysts as net income soars at Shire - Feb 22, 2008 ...contributed $38.9 million to the coffers, up 25%, while the ulcerative colitis therapy Pentasa (mesalamine) was up 27% to $48.7 million. Pharma Times (subscription), BUYINS.NET: (SLXP) SqueezeTrigger Price is $13.437. There is ... - Feb 21, 2008 In July 2002, Salix acquired the development rights in the United States to a granulated mesalamine product from Dr. Falk Pharma GmbH. Trading Markets (press release), Salix Announces Appointment of Mark Sirgo to Board of Directors - 06 Feb 2008 Current development projects include balsalazide tablet, metoclopramide-Zydis(R), encapsulated mesalamine granules, vapreotide acetate, and rifaximin for PharmaLive.com (press release), First and Only Once-Daily Mesalamine for Active, Mild to Moderate ... - Jan 29, 2008 MEZAVANT is the first and only Health Canada approved once-daily oral formulation of mesalamine, and the first mesalamine to be approved by Health Canada Canada NewsWire (press release), Axcan Pharma Reports Solid Start to Fiscal 2008, With Revenue of ... - Jan 31, 2008 In June 2007, the FDA published draft guidance on the type of clinical program required for the approval of mesalamine suppositories. FOXBusiness Study Data Show Asacol(R) (Mesalamine) is Effective in Treating ... - Dec 5, 2007 Asacol is a delayed-release oral mesalamine tablet indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets CNNMoney.com Nationwide Survey Reveals Differing Physician and Patient ... - Dec 7, 2007 At the time the surveys were fielded (prior to the availability of a once-daily mesalamine), patients reported they found it difficult to adhere to Reuters Alba Inks Ex-US/Japan Deal With Shire For Celiac Drug - Dec 14, 2007 ...its global experience in the gastrointestinal market through sales of the ulcerative colitis drugs Pentasa (mesalamine) and Lialda (mesalamine oral), BioWorld Online, Shire launches Mezavant XL in the UK - Nov 22, 2007 According to Cosmo, Mezavant XL is the first and only EU approved once-daily oral formulation of mesalamine 5-aminosalicyclic acid, a first-line treatment Pharmaceutical Business Review Axcan Pharma Continues its Solid Growth Trend, Closing Fiscal 2007 ... - Nov 29, 2007 In June 2007, the FDA issued draft guidance on the type of clinical program required for the approval of mesalamine suppositories. Based on this guidance, CNNMoney.com Alba Therapeutics Corporation and Shire plc Enter Into $325 ... - Dec 14, 2007 ..."We are excited about this opportunity for Shire to expand its GI franchise beyond mesalamine-related products such as Lialda(TM) / MEZAVANT XL(R). CNNMoney.com Shire snaps up Alba's gastrointestinal drug for $325m - Dec 17, 2007 ...to bring these novel therapies to patients." Shire already has a number of mesalamine-related gastrointestinal drugs, including Lialda/Mezavant and Pentasa. DrugResearcher.com, Research and Markets: Shire Spends over Us$8 Billion on ... - Nov 29, 2007 Vyvanse (lisdexamphetamine dimesylate) Gastrointestinal Pentasa (mesalamine) Human Genetic Therapies Replagal (agalsidase) Elaprase (idursulfase) Renal Reuters Perceptions of physicians and patients differ on the impact of ... - Dec 8, 2007 At the time the surveys were conducted (prior to the availability of a once-daily mesalamine), patients reported that the medication dosing schedules were a DailyIndia.com, Salix Pharmaceuticals to Present at Piper Jaffray Health Care ... - Nov 21, 2007 Current development projects include balsalazide tablet, metoclopramide-Zydis(R), encapsulated mesalamine granules, vapreotide acetate, and rifaximin for PR-Inside.com (Pressemitteilung), MMX Mesalamine Induces Remission in Patients With Mild or Moderate ... - Oct 23, 2007 Investigators examined the efficacy results from a long-term study that combined data from two randomised phase 3 studies of MMX mesalamine. DG News Rapid Symptom Resolution With Delayed Release Mesalamine in Mildly ... - Oct 24, 2007 By Danny Kucharsky PHILADELPHIA, PA -- October 24, 2007 -- Patients with mild and moderate ulcerative colitis who received 2.4 g daily of mesalamine DG News Mesalamine Related With Decreased Colorectal Cancer Rates - Oct 19, 2007 A study presented at the 72nd Annual Scientific Meeting of the American College of Gastroenterology has indicated that the use of mesalamine among patients MedIndia, Most Patients With Ulcerative Colitis Remain in Remission After 12 ... - Nov 2, 2007 In a related study, MMX mesalamine was efficacious for remission maintenance of both mild and moderate ulcerative colitis. The first study was presented Medscape (subscription) Salix Pharmaceuticals Reports 3Q2007 Results - Nov 6, 2007 ...“Also during the quarter we announced the successful completion of two Phase III trials to assess the efficacy and safety of our granulated mesalamine for Business Wire (press release), Ulcerative colitis - Oct 30, 2007 First-line medical therapies contain mesalamine (also known as 5-aminosalicylic acid [5-ASA]), which acts topically from the colonic lumen to suppress the AAFP News Now Further Upgrade to 2007 Financial Guidance Based on Strong Revenue ... - Nov 1, 2007 In Q3 2007 lialda's average share of the US oral mesalamine prescription market was 5.4%. lialda's product sales for the three months to September 30, Earthtimes, Shire goes from strength to strength with its ADHD drugs - Nov 2, 2007 ...contributed $40.7 million tothe coffers, up 26%, while the ulcerative colitis therapy Pentasa(mesalamine) was up 18% to $43.7 million. Pharma Times (subscription), Salix Pharmaceuticals Announces 3Q2007 Financial Results ... - Oct 23, 2007 SANVAR ® IR (vapreotide acetate), balsalazide tablet, granulated mesalamine and XIFAXAN ® for additional indications are under development. Business Wire (press release), : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |